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Obese individuals more frequently suffer from infections, as a result of increased
susceptibility to a number of bacterial pathogens. Furthermore, obesity can alter
antibiotic treatment efficacy due to changes in drug pharmacokinetics which can
result in under-dosing. However, studies on the treatment of bacterial infections in the
context of obesity are scarce. To address this research gap, we assessed efficacy
of antibiotic treatment in diet-induced obese mice infected with the Lyme disease
pathogen, Borrelia burgdorferi. Diet-induced obese C3H/HeN mice and normal-weight
controls were infected with B. burgdorferi, and treated during the acute phase of
infection with two doses of tigecycline, adjusted to the weights of diet-induced obese
and normal-weight mice. Antibiotic treatment efficacy was assessed 1 month after the
treatment by cultivating bacteria from tissues, measuring severity of Lyme carditis, and
quantifying bacterial DNA clearance in ten tissues. In addition, B. burgdorferi-specific
IgG production was monitored throughout the experiment. Tigecycline treatment was
ineffective in reducing B. burgdorferi DNA copies in brain. However, diet-induced obesity
did not affect antibiotic-dependent bacterial DNA clearance in any tissues, regardless
of the tigecycline dose used for treatment. Production of B. burgdorferi-specific IgGs
was delayed and attenuated in mock-treated diet-induced obese mice compared to
mock-treated normal-weight animals, but did not differ among experimental groups
following antibiotic treatment. No carditis or cultivatable B. burgdorferi were detected
in any antibiotic-treated group. In conclusion, obesity was associated with attenuated
and delayed humoral immune responses to B. burgdorferi, but did not affect efficacy of
antibiotic treatment.
Keywords: Borrelia burgdorferi, Lyme disease, bacterial infection, antibiotics, tigecycline, obesity, diet-induced
obesity, humoral response
INTRODUCTION
Obesity is a complex metabolic condition that affects more than 13% of the world population
(World Health Organization, 2015). The prevalence of obesity is even higher in North American
countries, where almost 30% of the population is considered obese (Finucane et al., 2011). Obesity
comorbidities include metabolic syndrome, cardiovascular disease and type 2 diabetes (Guh et al.,
2009; O’Neill and O’Driscoll, 2015). Emerging evidence suggests that obesity is also associated with
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increased susceptibility to bacterial infections and severity of
infection outcomes (Huttunen and Syrjänen, 2013). Obese
patients are more frequently diagnosed with respiratory, skin and
urinary infections, and are more prone to hospital-acquired and
surgical-site infections (Waisbren et al., 2010; Kwong et al., 2011;
Sreeramoju et al., 2011; Semins et al., 2012). Bacterial infections
therefore significantly reduce quality of life among obese patients.
However, studies on the treatment of bacterial infections in obese
populations are scarce.
Successful treatment of infection relies on achieving the
appropriate plasma and tissue drug concentrations over time
that is required to inhibit or kill the pathogen. Antibiotic
dosing is determined based on the antibiotic susceptibility
of individual pathogens (minimal inhibitory and bactericidal
concentrations; MIC and MBC) and the kinetics of antibiotic
distribution and clearance from the body (pharmacokinetics).
In obese patients, pharmacokinetic properties of antibacterial
agents can be affected in numerous ways including decreased
drug distribution due to partitioning of lipophilic drugs
in enlarged adipose tissue, increased drug excretion caused
by glomerular hyperfiltration, and increased drug volume
distribution (Falagas and Karageorgopoulos, 2010). Antibiotic
dosage can be adjusted based on the total body weight or
ideal body weight, with hydrophilic antibiotics likely to be
adjusted for the former and lipophilic for the latter (Falagas
and Karageorgopoulos, 2010). Other factors that have to be
considered when designing optimal dosing include antibiotic
toxicity and induction of antibiotic resistance in bacteria when
using subtherapeutic doses (pharmacodynamics) (Pai, 2015;
Drusano et al., 2016). Therefore, antibiotic dosing in obesity is
a complex problem.
Animal models of obesity recapitulate associated
complications of obesity in humans, including features
of metabolic syndrome (hypertension, hyperglycemia,
hyperlipidemia, and hypercholesterolemia). Since human obesity
often stems from excessive caloric intake and consumption of
energy-dense meals, the animal model which best approximates
human obesity is high fat diet-induced obesity (DIO) (Lutz
and Woods, 2012). DIO mice exhibit an attenuated ability to
control infection by Staphylococcus aureus, Porphyromonas
gingivalis and the Lyme disease pathogen Borrelia burgdorferi
(Amar et al., 2007; Yano et al., 2012; Farnsworth et al., 2015;
Zlotnikov et al., 2016). We and others have recently reported
that DIO, as well as severe obesity-independent hyperglycemia
and obesity-independent hypercholesterolemia, in mice inhibit
control of B. burgdorferi burden and/or tissue clearance of
bacterial DNA, and are associated with altered innate and
adaptive immune responses to this bacterium (Toledo et al.,
2015; Javid et al., 2016; Zlotnikov et al., 2016). Thus, obesity
and metabolic conditions associated with obesity can alter the
outcomes of infection with the Lyme disease pathogen in mouse
models.
Lyme disease is a tick-born infection that is increasingly
common in many North American and European countries
where obesity is highly prevalent (Finucane et al., 2011; Mead,
2015). Clinical manifestations of Lyme disease include a
characteristic rash at the site of a tick bite (erythema migrans),
inflammation of the heart and joints (Lyme carditis and
Lyme arthritis, respectively) and neurological complications
(neuroborreliosis). The most widely used animal model of
Lyme disease, C3H mice, recapitulates manifestations of
carditis and arthritis. However, similar to all other mouse
models, C3H mice are resistant to skin and neurological
manifestations. Lyme disease in humans is routinely treated
with the antibiotics doxycycline and ceftriaxone, and there
are no clinically relevant strains of antibiotic-resistant
B. burgdorferi (Wormser et al., 2006). Currently, there are
no specific guidelines for antibiotic treatment of Lyme disease
in obese patients (Wormser et al., 2006; Borchers et al.,
2015).
Borrelia burgdorferi DNA can be detected in tissues of infected
hosts including humans, mice, dogs and non-human primates
long after clinical symptoms of infection have resolved, as well
as after antibiotic treatment (Nocton et al., 1994; Straubinger
et al., 1997; Bockenstedt et al., 2002; Hodzic et al., 2008, 2014;
Barthold et al., 2010; Yrjänäinen et al., 2010; Embers et al.,
2012). There is controversy over whether this DNA derives from
live bacteria or uncleared bacterial debris, and whether residual
bacteria or their debris can continue to induce pathology in hosts
(Wormser and Schwartz, 2009; Bockenstedt and Radolf, 2014).
Interpretation of studies of this problem conducted in mouse
models of Lyme disease are complicated by differences in the
pharmacokinetic properties of the antibiotics used for clinical
treatment of this disease, which differ in mice and humans
(Wormser and Schwartz, 2009).
The tetracycline derivative tigecycline has a longer half-
life in mice than doxycycline and ceftriaxone, and has been
used to study B. burgdorferi persistence after infection and
antibiotic treatment (Barthold et al., 2010). Tigecycline belongs
to the class of lipophilic antibiotics, which generally require
higher dosage to achieve appropriate serum concentrations
in obese individuals (Falagas and Karageorgopoulos, 2010).
Pharmacokinetic studies have found no effect of obesity on
tigecycline serum concentration or urine clearance in healthy
adult humans (Pai, 2014), but increased weight and body
surface area are associated with increased tigecycline clearance
in individuals with skin infections and pneumonia, many
of whom have significant comorbidities (Wart et al., 2006;
Rubino et al., 2010). The effects of obesity on tigecycline
pharmacokinetics and efficacy in mice have not been
studied.
We found recently that DIO in C3H/HeN mice is associated
with attenuated innate immune responses to B. burgdorferi,
reduced tissue clearance of B. burgdorferi DNA and increased
severity of Lyme carditis (Zlotnikov et al., 2016). At a
late acute stage of infection (4 weeks post-inoculation), the
effect of DIO is most pronounced in female mice, where
bacterial DNA burden in DIO was increased by ∼4-fold across
all tissues, with ∼2–17-fold increases in burden observed
in the brain, heart, knee joint, liver and lung (Zlotnikov
et al., 2016). In the present study, we investigated whether
efficacy of antibiotic treatment of B. burgdorferi infection
is altered in the context of DIO in female C3H/HeN
mice.
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FIGURE 1 | Mouse model of antibiotic treatment of B. burgdorferi infection. (A) Weights of mice were measured throughout the course of the experiment.
DIO mice are shown in black (gray margins) and NW mice in white. Box and whiskers represent means with 95% confidence intervals (CI). Gray dotted lines and
shaded areas represent the time of infection and the period of antibiotic treatment, respectively. ∗ indicates p < 0.05 within individual time points (two-way ANOVA
with Holm-Sidak post-tests). (B) Experimental scheme. DIO mice are depicted in gray, NW mice in white. “NW” and “obese” doses consisted of 12.5 mg/kg of
tigecycline adjusted to the average weight of lean or DIO mice at the beginning of the treatment (32.5 and 42.7 g, respectively. See Material and Methods for details).
MATERIALS AND METHODS
Ethics Statement
This study was carried out in accordance with the
recommendations of the Guide to the Care and Use of
Experimental Animals by the Canadian Council on Animal Care.
The protocol was approved by the University of Toronto Animal
Care Committee (permit #20011501). Borrelia burgdorferi was
handled in accordance with guidelines of the University of
Toronto, Public Health Agency of Canada and Canadian Food
Inspection Agency (permit #12a-M30-2).
Animals
Four-week old female C3H/HeN mice were purchased from
Charles River (Montréal, QC, Canada). Mice were housed in
groups of four per cage under pathogen-free conditions with
environment enrichment. Immediately upon arrival, mice were
randomly assigned to one of two groups and fed ad libitum
with high-fat diet (Teklad TD.06414, Harlan Laboratories, Inc.,
Mississauga, ON, Canada) or standard rodent chow (Teklad 2018
Rodent Chow, Harlan Laboratories). Mice preconditioned on
high-fat diet received 18.4, 21.3, and 60.3% kcal from protein,
carbohydrate and fat, respectively. Mice preconditioned on
normal diet consumed 20.1, 69.8, and 10.2% kcal from protein,
carbohydrate and fat, respectively. High-fat diet-fed mice were
obese (DIO: body weight > 25% of weight of age-matched
mice fed normal diet: normal weight, NW) (Figure 1A). All
experimental animals, including mock-infected controls, were
transferred to a biosafety level 2 (BSL2) room within the
same animal care facility the day before infections and mock-
infections, and were housed in this room for the remaining
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duration of experiments. Food, housing and environmental
enrichments conditions were similar in BSL1 and BSL2 rooms.
At the experimental end point, mice were anesthetized with
10 mg/kg xylazine (MTC Pharmaceuticals, Cambridge, ON,
Canada) and 200 mg/kg ketamine hydrochloride (Rogar/STB,
Montréal, QC, Canada), and sacrificed by cervical dislocation.
B. burgdorferi Strains
For all following experiments, infectious B31 5A4-derived
GFP-expressing B. burgdorferi strain was used (Moriarty
et al., 2008). B. burgdorferi was grown in Barbour-Stoenner-
Kelly (BSK-II) medium at 36◦C and 1.5% CO2 (Barbour,
1984; Moriarty et al., 2012). Where needed, BSK-II was
supplemented with 100 µg/ml gentamycin (Bioshop, Burlington,
ON, Canada) (BSK-II-G) and 1X Borrelia antibiotic mixture
containing 20 µg/ml phosphomycin (Sigma–Aldrich, Oakville,
ON, Canada), 50 µg/ml rifampicin and 2.5 µg/ml amphotericin
B (both from Bioshop). For all experiments, freshly inoculated
B. burgdorferi cultures were grown to a logarithmic phase (less
than 8× 107 cells/ml).
Borrelia burgdorferi gradually loses plasmids required for
infectivity during in vitro passaging (Thomas et al., 2001).
To ensure that B. burgdorferi used for experiments were fully
infectious, we passaged the infectious B31 5A4-derived GFP-
expressing B. burgdorferi strain GCB726 (Moriarty et al., 2008)
through a mouse. A total number of 104 bacteria in 100 µl
BSK-II-G were subcutaneously injected at the dorsal lumbar
midline of a C3H/HeN mouse. The mouse was sacrificed 3 weeks
post-infection and B. burgdorferi were recovered from tibiotarsal
joints by incubation in 5 mL BSK-II-G supplemented with 1X
Borrelia antibiotic mixture. The resulting B. burgdorferi strain
was denoted TMB79, passaged once, and frozen in glycerol at
−80◦C. TMB79 used for subsequent experimental infections was
grown fresh from these glycerol stocks.
Determination of Minimal Inhibitory and
Bactericidal Concentrations of
Tigecycline
To determine the concentrations of tigecycline to be used
for treating B. burgdorferi-infected mice, we first determined
the minimal inhibitory and bactericidal concentrations (MIC
and MBC, respectively) for B. burgdorferi strain TMB79. To
determine the MIC, twofold serial dilutions of tigecycline in
BSK-II-G (from 50 to 0.1 mg/l) were prepared in a 96-well
plate (Nunc/ThermoFisher Scientific, Mississauga, ON, Canada).
Biological triplicates of B. burgdorferi logarithmic cultures were
inoculated into the wells with antibiotics to a final concentration
of 2 × 106 cells/ml per well. Plates were incubated for 48 h
and the number of motile B. burgdorferi per well was counted
using a Petroff-Hausser chamber (Hausser Scientific, Horsham,
PA, USA) and darkfield microscope. Non-motile bacteria were
thinner, no longer luminous under darkfield microscopy and had
disruptions in their normal sine wave morphology. The MIC
was defined as the lowest tigecycline concentration at which the
number of motile B. burgdorferi did not exceed the number of
bacteria used for the initial inoculation, as previously described
Barthold et al. (2010). To determine the MBC, 50 µl from each
of the triplicate wells in MIC experiments were inoculated into
5 ml of BSK-II-G (total inoculum was 150 µl). The MBC was
the lowest tigecycline concentration at which cultures remained
negative (no B. burgdorferi present) after 21 days of incubation,
as previously defined Barthold et al. (2010). All plates were kept
at 36◦C and 1.5% CO2 without shaking.
Experimental Infections and Antibiotic
Treatment
After 12 weeks of diet preconditioning, mice were randomly
assigned to eight experimental groups with 10 mice per group.
Three groups of DIO and three groups of NW mice were
subcutaneously injected at the dorsal lumbar midline with 104
B. burgdorferi (strain TMB79) in 100 µl of BSK-II-G. One group
of DIO and one group of NW mice were injected with 100 µl
of BSK-II-G medium alone (“mock-infected”). Three weeks post-
inoculation, two groups of B. burgdorferi-infected DIO and two
groups of B. burgdorferi-infected NW mice were treated daily for
10 consecutive days by intraperitoneal injection with 12.5 mg/kg
tigecycline (LKT Laboratories Inc., St. Paul, MN, USA) (Barthold
et al., 2010). One of each of the infected DIO and NW groups was
treated with a “normal dose” of tigecycline, which was calculated
based on the average weight of the NW group at treatment
onset (32.46 g: Figure 1A). One of each of the infected DIO
and NW groups was treated with “obese dose” tigecycline, which
was calculated based on the average weight of the DIO group
at treatment onset (42.65 g: Figure 1A). One of each of the
infected DIO and NW groups was also treated over the same
treatment period with vehicle only (“mock-treated”: 10% DMSO
in 0.9% saline). Since tigecycline is highly unstable in saline
(Barthold et al., 2010), antibiotic solutions were prepared daily
from 10X stock solutions (filter-sterilized tigecycline in DMSO,
frozen at−20◦C in single-use aliquots). The experimental scheme
is visually summarized in Figure 1B.
Measurement of B. burgdorferi DNA
Copy Number in Target Tissues
DNA was isolated from heart, patella (knee joint), quadriceps
muscle, bladder, ear, skin, brain, liver, and lung from sacrificed
animals using PureLink Genomic DNA Mini Kit according to
manufacturer’s instructions (ThermoFisher Scientific). Isolated
DNA was used as a template for quantitative real-time PCR
(qPCR) measurement of B. burgdorferi flaB DNA copy number,
as recently described (Javid et al., 2016). Runs with R2 values
lower than 0.9 and/or amplification efficiency that was not
within the range of 85 – 120 % were repeated. Each genomic
DNA sample was run in six technical replicates. flaB DNA copy
numbers in each sample were quantified using a standard curve
consisting of technical duplicates of 10-fold serial dilutions of
plasmid DNA pTM222 (Lee et al., 2010) containing a known
copy number of flaB DNA (107 – 1 copies). After inspection of
all melt curves to identify and eliminate all products without the
correct melting temperature for the flaB amplicon, the average
copy number of flaB DNA in each sample was normalized to the
DNA concentration of the same sample to control for possible
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differences in DNA extraction efficiency. To control for possible
false positive results (stemming from stochastic amplification
and/or amplification of non-B. burgdorferi flaB DNA sequences
with a similar amplicon melting profile from tissues), we set a
threshold for each tissue by calculating the mean amplification
value for the corresponding tissue isolated from mock-infected
animals plus two times standard deviation of the mean for mock-
infected samples. Samples were considered qPCR-positive if the
average flaB copy number was higher than the threshold.
Histology and Carditis Scoring
Sagittal sections of hearts harvested from sacrificed mice were
placed in 10% neutral buffered formalin (Sigma Aldrich),
which was changed after 24 h of fixation. Samples were
subsequently embedded in paraffin, sectioned and stained
with hematoxylin and eosin (H&E; Toronto Centre for
Phenogenomics, Toronto, ON, Canada). Carditis scoring was
performed using a modified protocol for quantifying multifocal
cardiac inflammation (Diebold et al., 1995), as recently described
Javid et al. (2016) and Zlotnikov et al. (2016). The numbers
of nuclei in five 100 mm2 regions of interest (located in each
atrium and ventricle and the heart apex) in 3 matched sagittal
sections were enumerated using a counting grid and averaged for
each heart. The majority of each region of interest consisted of
myocardium.
Serum Collection and Measurement of
Anti-B. burgdorferi IgM and IgG Titers
Approximately 100 µl of blood was collected from saphenous
veins of mice using microvettes (Sarstedt, Montréal, QC, Canada)
at three different time points: pre-immune (1 week before
B. burgdorferi inoculation), post-inoculation (2 weeks after
B. burgdorferi inoculation) and post-treatment (5 weeks after
B. burgdorferi inoculation, 2 weeks after last antibiotic treatment).
Serum was collected after spinning microvettes for 5 min at
10,000 × g at room temperature (22–25) (Microfuge 22R
centrifuge with fixed-angle rotor, Beckman Coulter, Mississauga,
ON, Canada), and stored immediately at −80◦C until thawing
for analysis. Serum was also collected from blood obtained by
cardiac punctures at the experimental endpoint (7 weeks after
B. burgdorferi inoculation, 4 weeks after last antibiotic treatment),
and processed in the same manner.
Borrelia burgdorferi cells were harvested, resuspended to a
final density of 1 × 109 cells/ml, and processed as described
previously (Lourdault et al., 2009; Eshghi et al., 2015). Ninety-
six-well ELISA plates (Nunc-Immuno/ThermoFisher Scientific)
were coated with 100 µl of the B. burgdorferi whole cell
lysate. All incubation steps were performed at 37◦C for
1 h, and were followed by washing with 0.05% Tween 20
in 1X phosphate-buffered saline (PBS-T). Firstly, plates were
incubated with blocking buffer (0.5% skim milk in PBS-T).
Secondly, diluted mouse serum (1:100 or 1:700 dilutions) was
added to each well in technical duplicates. Finally, plates were
incubated with 1:10,000 diluted HRP-tagged goat anti-mouse
IgG antibody (Abcam, Toronto, ON, Canada). To detect bound
secondary antibodies, ABTS substrate (Roche, Mississauga, ON,
Canada) was added to each well. After 1 h incubation at
room temperature, absorbance was measured at 405 nm (A405;
for detection of the ABTS conversion) and 492 nm (A492;
reference wavelength for detection of non-specific products)
using a CLARIOStar plate reader (BMG LabTech, Guelph, ON,
Canada). Final IgG concentrations were plotted as A405 values
corrected by subtraction of blank values (A405 values of wells
not coated with B. burgdorferi whole cell lysate and processed
as described above), and reference A492 values. Concentrations
of B. burgdorferi specific IgMs were determined following the
protocol described above using pooled individual serum samples
from each experimental group (diluted 1:100) and HRP-tagged
goat anti-mouse IgM antibodies (Abcam) at 1:10,000 dilution.
Normal mouse serum and serum from untreated B. burgdorferi-
infected mice were used on every plate as negative and positive
controls, respectively.
Statistical Analysis
Statistical analysis was performed using GraphPad Prism v.6.0
software (GraphPad Software, La Jolla, CA, USA). Data in
Figures 1A, 2A–C, and 3B–D were analyzed by two-way ANOVA
with Holm-Sidak post-tests. Values in Figure 2B were log-
transformed prior to statistical analysis. Pre-immune (non-
specific) IgG levels of DIO and NW mice were compared using
unpaired parametric t-test. Comparisons with p < 0.05 were
considered statistically significant, and are indicated by asterisk
(∗) in the figures.
RESULTS
Antibiotic Treatment of B. burgdorferi
Infection in DIO Mice
In the present study, we examined whether DIO affected efficacy
of treatment with the antibiotic tigecycline in female C3H/HeN
mice. Tigecycline was chosen because it has a significantly longer
half-life in mice than other antibiotics commonly used for
experimental treatment of acute B. burgdorferi infection, and is
therefore more appropriate for studying treatment efficacy in
mice than antibiotics which are commonly used to treat human
infection, such as doxycycline and ceftriaxone (Bockenstedt et al.,
2002; Hodzic et al., 2008; Barthold et al., 2010). Mice were treated
in the acute phase of infection (3 weeks post-inoculation), and
antibiotic treatment efficacy was assessed 4 weeks post-treatment
(8 weeks post-inoculation). This corresponded to a late, typically
post-resolution infection in mock-treated mice (Barthold et al.,
1993).
To ensure full infectivity of B. burgdorferi used for the
experiments, the B31 5A4-derived strain GCB726 (Moriarty
et al., 2008, 2012; Javid et al., 2016; Zlotnikov et al., 2016) was
passaged through a mouse. The resulting strain was denoted
TMB79 (see Materials and Methods for details), and minimum
inhibitory and bactericidal concentrations (MIC and MBC)
of tigecycline for TMB79 were determined. MIC and MBC
values were 0.4 ± 0 and 1.6 ± 0 mg/l, respectively, and were
approximately 70- and 2-fold greater than the respective MICs
and MBCs for B. burgdorferi B31 strains reported in other
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FIGURE 2 | Diet-induced obesity has no effect on tissue clearance of B. burgdorferi in antibiotic-treated mice. Bacterial DNA in tissues of mice was
quantified by qPCR with primers specific to the B. burgdorferi flaB gene. DIO mice are shown in black and NW mice in white. Individual values from mock-treated
groups are depicted as triangles. Squares and circles stand for values measured in groups treated with “NW” and “Obese” doses of tigecycline, respectively.
(A) Percentage of qPCR-positive tissues per mouse. Dotted line represents the average percentage of positive tissues in NW mock-treated mice (47%). Bars
correspond to means with 95% CI. (B) flaB DNA copy number in all tissues of individual mice, calculated from individual copy numbers measured in ear, bladder,
skin, knee joint (patella), brain, kidney, quadriceps, heart, lung and liver. Copy number is normalized to 1 µg of total host and bacterial DNA in each sample (data for
individual tissues are provided in Supplementary Figures S1 and S2). Dotted line represents the median flaB DNA copy number in tissues of mock-treated NW mice
(8.4ˆ103 flaB DNA copies/µg DNA). Bars display medians with 95% CI. (C,D) Carditis severity. Sagittally hemisected hearts were fixed and stained by hematoxylin
and eosin (H&E). (C) Numbers of nuclei per 100 mm2 region of interest, calculated from counts obtained in five regions of interest (each atrium and ventricle and the
heart apex) in three matched H&E stained sections of heart. DIO mice are shown in black (gray margins) and NW mice in white. Means with 95% CI are shown.
(D) Representative heart sections. Bars correspond to 50 µm (40x magnification). ∗ indicates p < 0.05 (two-way ANOVA with Holm-Sidak post-tests; values in
(B) were log-transformed prior to statistical analysis). NS, no significant differences among any groups (two-way ANOVA with Holm-Sidak post-tests).
studies (MIC 0.006–0.016 mg/l and MBC = 0.195–1 mg/l)
(Yang et al., 2009; Ates et al., 2010; Barthold et al., 2010). The
difference between previously reported MIC values of B31 strains
and the MIC value of the TMB79 strain was not caused by
the passage through a mouse, since the MICs of tigecycline
before and after the passage were identical (0.4 ± 0 mg/l).
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Tigecycline efficacy in NW mice is best approximated from the
pharmacokinetic/pharmacodynamic parameter f AUC0−24/MIC
[area under the free drug concentration-time curve from 0 to 24 h
(AUC0−24) over the MIC of the pathogen; Crandon et al., 2009].
Based on available studies, f AUC0−24/MIC in the present study
was estimated to be 2.8–5.2 (Crandon et al., 2009; Koomanachai
et al., 2009), which corresponds to the tigecycline exposure
required to arrest bacterial growth in NW mice (Crandon et al.,
2009; Nicasio et al., 2009).
To study the effects of DIO on antibiotic treatment, 80
4-week old female C3H/HeN mice were preconditioned for
12 weeks with either a high fat diet (40 mice) or normal
rodent chow (40 mice). After 11 weeks of preconditioning,
mice fed a high fat diet weighed 38% more than normal chow
controls (NW) (Figure 1A), and were therefore obese (DIO).
Similar to recent results of previous studies (Shi et al., 2006,
4), DIO was not associated with significant increases in non-
fasting blood glucose in female C3H/HeN mice compared to NW
control animals after 18 weeks of preconditioning (7.989 ± 0.89
and 6.85 ± 0.66 mmol/l for DIO and NW mice, respectively;
p > 0.05).
As summarized in the experimental flow chart provided
in Figure 1B, after 12 weeks of preconditioning, 30 mice in
each diet group were infected by needle inoculation at the
dorsal lumbar midline with 1 × 104 B. burgdorferi strain
TMB79. Ten mice in each diet group were mock-infected
with B. burgdorferi cultivation medium alone (“mock-infected”).
Three weeks after B. burgdorferi infection (15 weeks from
beginning of diet regimens), infected mice in each diet group
were further subdivided into 3 groups of 10. Two of these
infected groups for each diet were treated with intraperitoneal
tigecycline injections every 24 h for 10 days, whereas the third
group was injected with tigecycline vehicle alone (10% DMSO
in 0.9% saline: “mock-treated”). Similarly, the mock-infected
controls were treated with vehicle only. To simulate conditions
of antibiotic under-treatment in obesity, NW and DIO infected,
antibiotic-treated mice were sub-divided into 2 groups of 10
animals. One each of these NW and DIO groups was treated daily
with 406.25 µg of tigecycline (normal weight dose: “NW dose”),
which corresponded to a 12.5 mg/kg dose calculated based on
the mean weight of NW mice at time of treatment onset (32.5 g).
The second of these NW and DIO groups was treated daily with
533.75 µg of tigecycline (“Obese dose”), which corresponded to
a 12.5 mg/kg dose calculated based on the mean weight of DIO
mice at time of treatment onset (42.7 g).
Borrelia burgdorferi is a highly invasive bacterium that can
colonize the majority of mouse organs and tissues (Barthold
et al., 1990, 1991; Yang et al., 1994; Imai et al., 2013). To assess
the effects of DIO and antibiotic treatment on B. burgdorferi
clearance, hearts and joints were cultivated to recover viable
bacteria, and copies of B. burgdorferi flaB DNA were quantified
in 10 tissues (bladder, brain, ear, heart, kidney, liver, lung,
patella/knee joint, quadriceps muscle, and ventral thoracic skin)
by qPCR. B. burgdorferi infection in mice is accompanied by
prominent arthritis and carditis in the joints and heart (Barthold
et al., 1990). Hearts were collected at the experimental endpoint
for quantitative histological analysis of inflammation (carditis).
Severity of arthritis was not measured, since this phenotype
typically manifests in juvenile mice infected at 3–5 weeks of
age (Barthold et al., 1990), and mice used in the present
study were 16-week old adults at time of infection due to the
duration of dietary preconditioning. Furthermore, arthritis was
not observed in NW and DIO adults infected at a similar age
in our recent study (Zlotnikov et al., 2016). Since antibiotic
treatment can affect B. burgdorferi-specific antibody production
(Bockenstedt et al., 2002; Nowakowski et al., 2003; Barthold
et al., 2010; Elsner et al., 2015), IgMs and IgGs were measured
in sera from all 80 mice collected at four time points: 1 week
before infection (“pre-immune”), 2 weeks after infection (“post-
inoculation”), 2 weeks after the end of antibiotic treatment
(“post-treatment”: 45 days/∼6 weeks post-inoculation), and at
the experimental endpoint (4 weeks after the end of antibiotic
treatment, 59 days/∼8 weeks post-inoculation).
Effect of DIO on Tissue Clearance of
B. burgdorferi DNA in Antibiotic-Treated
Mice
Except for one joint of a DIO mock-treated mouse, no viable
spirochetes were recovered from hearts and tibiotarsal joints of
DIO or NW mice by cultivation. To the best of our knowledge,
no previous reports have described cultivation of B31-derived
B. burgdorferi strains from tissues of immunocompetent mice
after 8 weeks of infection with the same or lower infectious doses
than the dose used in our study. In addition, most previous
studies investigating infection at this time point or later have been
performed with the N40 B. burgdorferi strain (Bockenstedt et al.,
2002, 2012; Yrjänäinen et al., 2007, 2010; Hodzic et al., 2008,
2014). Since individual B. burgdorferi strains display differences
in infectivity and tissue tropism (Wormser et al., 2008), it is
possible that the inability to cultivate viable B. burgdorferi from
heart and joint at 8 weeks reflected strain-specific differences in
colonization of, or viability in, these tissues. Tissues in our study
were also cultivated in medium containing gentamicin, since the
TMB79 strain is resistant to this antibiotic due to the presence of
a selectable plasmid for expression of green fluorescent protein.
Although gentamicin resistance was not affected by passage of
the TMB79 parent strain GCB726 through a mouse after 3 weeks
of infection, it is possible that the loss of this plasmid during
infection prevented recovery of live bacteria at 8 weeks post-
infection.
Due to the extremely low rate of recovery of viable bacteria
from hearts and joints at this infection stage, we therefore
monitored clearance of bacterial DNA from tissues by measuring
B. burgdorferi flaB DNA copy number (Figure 2, Table 1). To
ensure that copy number measurements did not include false-
positive values arising from stochastic amplification of potentially
contaminating B. burgdorferi flaB DNA sequences or of other
flaB-like sequences with similar melt-curve profiles, qPCR was
performed in tissue samples from mock-infected mice, and
the background values (mean plus 2 standard deviations) were
subtracted for each tissue from the values for samples for the same
tissue from infected animals. The resulting flaB copy number
values were normalized to total µg of DNA in each reaction,
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TABLE 1 | Number of tissues positive for the presence of B. burgdorferi flaB DNA, as determined by qPCR.
DIO NW
Treatment group Mock-treated “NW dose” “Obese dose” Mock-treated “NW dose” “Obese dose”
Heart 5/10 0/10 0/10 1/10 0/10 0/10
Ear 10/10 3/10 3/10 10/10 1/10 4/10
Skin 9/10 0/10 0/10 10/10 0/10 0/10
Lung 3/10 0/10 0/10 2/10 0/10 0/10
Bladder 9/10 1/10 0/10 9/10 0/10 0/10
Brain 5/9 4/10 4/10 3/10 8/10 4/10
Kidney 1/10 5/10 0/10 1/10 5/10 0/10
Knee joint 8/10 3/8 2/10 10/10 0/10 5/10
Liver 0/10 1/10 0/10 0/10 1/10 2/10
Quadriceps 0/10 0/10 1/10 1/10 0/10 0/10
Results are summarized as number of positive tissues per number of analyzed individual tissues in each experimental group. Raw data for all tissues are provided in
Supplementary Figures S1 and S2. All tissues of DIO and NW mock-infected mice were qPCR negative.
to control for differences in cell density and DNA extraction
efficiency among tissues and individual samples.
The percentage of flaB-positive tissues/mouse (Figure 2A) and
median flaB DNA copy number per tissue (Figure 2B) were
comparable in DIO and NW mock-treated mice. At 4-weeks
post-inoculation, the flaB DNA copy number is most commonly
elevated in heart, brain, liver, lung, knee joint of DIO mice
(Zlotnikov et al., 2016). In the present study, the only tissue with
a greater flaB DNA copy number in mock-treated DIO animals
was heart (median 1,825-fold and mean 5.4-fold; Supplementary
Figure S1A). In contrast, the bacterial burden was elevated in
the ears of NW mock-treated mice when compared to their DIO
counterparts (median 3.9-fold and mean 3.5-fold; Supplementary
Figure S1B). Therefore, by a late stage of infection (8 weeks post-
inoculation), DIO in female mice was associated with elevated
bacterial DNA burden in heart only.
Despite the large fold difference in flaB DNA copy number
in the hearts of mock-treated DIO and NW mice, no carditis
was observed in any experimental group, as measured using a
sensitive nuclei counting-based carditis quantification method
(Figures 2C,D; Supplementary Figures S3 and S4) (Javid et al.,
2016). Carditis in B. burgdorferi-infected mice typically peaks at
2–4 weeks post-inoculation and declines thereafter (Armstrong
et al., 1992; Barthold et al., 1993; Bockenstedt et al., 2001;
Lasky et al., 2015), and it is likely that carditis had already
resolved by the endpoint of our studies. In mice fed a high
fat diet for prolonged periods, cardiomyocyte hypertrophy and
accumulation of extracellular matrix can also lead to reduced
cellular density in the heart (Wang et al., 2015). However, in the
present study, significant hypocellularity in the hearts of DIO
mice was not observed (Figures 2C,D; Supplementary Figures S3
and S4).
Across doses, tigecycline treatment resulted in a 73% and
a 68% reduction in the percentage of flaB-positive tissues
per mouse compared to DIO and NW mock-treated animals,
respectively (p < 0.05 for treated compared to mock-treated)
(Figure 2A). Full clearance from all tissues, determined by
identifying mice with no flaB-positive tissues, was observed in
1/20 (5%) DIO and 4/20 (20%) NW antibiotic-treated mice,
and did not differ significantly between diet groups (p > 0.05).
Across doses, the average flaB DNA copy number/tissue was
reduced by 256-fold and 95–fold respectively in tigecycline-
treated DIO and NW animals compared to mock-treated
controls (p < 0.05) (Figure 2B). The percentage of flaB-positive
tissues/mouse (Figure 2A) and median flaB copy number per
tissue (Figure 2B) also did not significantly differ among any
experimental groups following treatment with either “NW” or
“Obese” antibiotic doses. These results indicated that in the
context of whole mice (all 10 examined tissues) DIO did not affect
tigecycline-dependent clearance of B. burgdorferi DNA, and
that NW and obese weight doses were similarly effective. Since
no viable bacteria were recovered from any tissues, the DNA
measured in tissues could have been derived from uncleared
bacterial debris (Bockenstedt et al., 2012), or uncultivatable
bacteria remaining in tissues (Hodzic et al., 2014). However,
since DIO did not affect antibiotic-dependent B. burgdorferi DNA
clearance, additional experiments using previously described
transcription- or xenodiagnosis-based methods (Bockenstedt
et al., 2002; Hodzic et al., 2008) were not performed to determine
if the DNA remaining in tissues was derived from live bacteria.
At the level of individual tissues, heart (Supplementary Figure
S1A), skin (Supplementary Figure S1C) and lung (Supplementary
Figure S1D) were the only tissues completely cleared of
B. burgdorferi DNA after tigecycline treatment in all experimental
groups. In bladder, all but one of the DIO mice were qPCR
negative after antibiotic treatment (Supplementary Figure S1E).
In brain (Supplementary Figure S1F), DNA copy number was
comparable to or greater than mock-treated mice in most
antibiotic-treated groups, suggesting that tigecycline treatment
was not effective in this organ. In kidney (Supplementary Figure
S2A), copy number was higher in both NW and DIO mice
treated with the NW dose of tigecycline than in mock-treated
controls, whereas B. burgdorferi DNA was completely cleared
in kidneys following treatment with the higher, “Obese dose” of
tigecycline. In the knee joint (Supplementary Figure S2B) and ear
(Supplementary Figure S1B), antibiotic treatment significantly
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reduced but failed to clear B. burgdorferi DNA in most groups.
Liver (Supplementary Figure S2C) and quadriceps muscle
(Supplementary Figure S2D) were negative for B. burgdorferi
DNA in 9/10 mock-treated mice from both diet groups by 8 weeks
post-infection, and copy number did not differ significantly in
mock-treated and treated groups. Unlike in kidney, where 9/10
untreated mice were flaB-negative (Supplementary Figure S2A),
tigecycline treatment did not result in significantly increased copy
number in liver or quadriceps muscle (Supplementary Figures
S2C,D). Collectively, these results implied that DIO did not
reduce tigecycline treatment efficacy, but that, similar to previous
reports (Bockenstedt et al., 2002, 2012; Hodzic et al., 2008, 2014;
Barthold et al., 2010; Yrjänäinen et al., 2010), antibiotic treatment
itself did not eliminate B. burgdorferi DNA from several tissues,
including brain, kidney, knee joint and ear.
Effects of DIO on B. burgdorferi-Specific
Antibody Production in Untreated and
Antibiotic-Treated Mice
Finally, effects of DIO on B. burgdorferi-specific IgM and IgG
production were measured over the course of infection by
ELISA, using whole cell lysates of the same B. burgdorferi
strain used for infection as the ELISA antigen (Figure 3;
Supplementary Figure S5). Sera of mock-infected mice did
not contain B. burgdorferi-reactive IgMs or IgGs at any time
point. As expected (Barthold et al., 1991), B. burgdorferi-
specific IgM levels progressively declined through the course
of the experiment in both mock-treated and treated groups
(Supplementary Figure S5). The kinetics of IgG production in
various experimental groups were compared by normalizing
ELISA absorbance values to the median absorbance value for
infected, mock-treated NW mice at the experimental endpoint
(8 weeks after infection), after correcting for differences in ELISA
serum dilutions at different time points (Figure 3A; raw data
and results of statistical analysis are shown in Figures 3B–D).
B. burgdorferi-specific IgG production in mock-treated DIO
mice was delayed and attenuated compared to NW counterparts
within the 8-week study period (Figure 3A). B. burgdorferi-
specific IgG levels were lower in mock-treated infected DIO mice
than in NW counterparts at 6 and 8 weeks post-inoculation
(Figures 3C,D), indicating that production of antibodies in
response to B. burgdorferi was impaired in DIO.
In mice and humans, antibiotic treatment in Lyme disease can
result in reduced circulating IgG levels (Bockenstedt et al., 2002;
Nowakowski et al., 2003; Hodzic et al., 2008, 2014; Barthold et al.,
2010; Elsner et al., 2015). In mice, this is due to B. burgdorferi-
suppressed formation of the long-lived germinal centers required
for maintaining long-lived humoral immunity, and dependence
of antibody production on continued antigen stimulation-based
development of short-lived germinal centers (Elsner et al., 2015).
Similarly, B. burgdorferi-specific IgGs in both NW and DIO mice
were lower following antibiotic treatment than in mock-treated
controls at both 2 and 4 weeks post-treatment (6 and 8 weeks
post-infection) (Figures 3C,D). Therefore, tigecycline treatment
led to attenuated B. burgdorferi-specific IgG production, likely
due to reduction of the amount of bacterial antigen driving
humoral immune responses. This is supported by a strong
correlation between IgG levels at both 6 and 8 weeks post-
inoculation (2 and 4 weeks post-treatment) and a total number
of flaB DNA copies in tissues of B. burgdorferi-infected mice
across diet and treatment groups (both p< 0.0001, as determined
by Spearman correlation). Serum IgG levels were similar in all
groups of tigecycline-treated mice (p > 0.05; Figures 3C,D),
indicating that neither DIO nor antibiotic dose significantly
affected IgG production in treated animals. Collectively, these
results indicated that production of B. burgdorferi-specific IgGs
was delayed and attenuated in DIO and that antibiotic treatment
inhibited generation of specific IgGs in both diet groups, but that
the inhibitory effects of DIO and tigecycline treatment on IgG
production were not additive.
DISCUSSION
In this study, we found that DIO does not affect tigecycline-
dependent clearance of B. burgdorferi DNA from tissues of female
C3H/HeN mice, and that calibrating treatment dose to average
body mass does not significantly alter clearance efficacy. Thus,
DIO does not impair the efficacy of tigecycline treatment initiated
at an acute phase of B. burgdorferi infection. These results provide
valuable information about the efficacy of tigecycline treatment in
facilitating clearance of bacterial DNA from a range of tissues in
both NW and DIO mice, as well as further insight into the effects
of DIO on immune responses to B. burgdorferi infection.
In the acute stage of B. burgdorferi infection in female mice
(4 weeks post-inoculation), tissues affected by DIO include heart,
brain, knee joint, liver and lung (Zlotnikov et al., 2016). By
8 weeks B. burgdorferi DNA had been largely cleared from
liver and lung in both NW and DIO groups, and there was
no significant difference in bacterial burden in the knee joint
and brain between DIO and NW mice. Therefore, the heart
was the only organ where impaired B. burgdorferi clearance
in DIO continued into late infection stages in female animals.
Although we and others have found that metabolic disorders such
as obesity-independent hyperglycemia and hypercholesterolemia
in mice inhibit control of B. burgdorferi burden and/or tissue
clearance of bacterial DNA (Toledo et al., 2015; Javid et al.,
2016), female DIO mice were not hyperglycemic (Shi et al., 2006),
and DIO alone does not induce hypercholesterolemia in mice
without concomitant deficiencies in apolipoprotein E or low
density lipoprotein receptor (Karagiannides et al., 2008). Thus,
increased burden in the heart at late infection stages was not
due to hyperglycemia or hypercholesterolemia. Passive transfer
of immune serum to B. burgdorferi facilitates clearance of some
but not all bacterial DNA from heart (Barthold et al., 2006),
suggesting that deficits in IgG production in female mice with
DIO likely contributed to elevated burden in this tissue. A similar
effect of DIO on specific IgG production and control of bacterial
load has recently been reported for S. aureus infections in mice
(Farnsworth et al., 2015).
Our data showed that tigecycline treatment did not
significantly reduce B. burgdorferi DNA copy number in brain.
Comparable to other antibiotics, most of which do not cross
Frontiers in Microbiology | www.frontiersin.org 9 February 2017 | Volume 8 | Article 292
fmicb-08-00292 February 22, 2017 Time: 15:3 # 10
Peˇtrošová et al. Antibiotic Efficacy in Diet-Induced Obesity
FIGURE 3 | Reduced B. burgdorferi-specific serum IgGs in DIO mice. (A) Development of B. burgdorferi-specific IgG responses in DIO and NW mice during
infection and tigecycline treatment. DIO and NW mice are depicted as black and white shapes (with black and gray lines, respectively). Mice from mock-treated
groups are represented by triangles. Mice treated with “NW” and “Obese” doses of tigecycline are depicted as squares and circles, respectively. The shaded area
represents the period of antibiotic treatment. To facilitate visual comparison among groups and time points, serum dilution-corrected IgG levels were normalized to
median IgG levels measured in NW mock-treated mice 8 weeks post-infection (100%; dotted line). Shown are median values in each group. Raw values which were
not corrected for serum dilution or normalized to the NW mock 8 week control group are shown in (B–D). Non-normalized A405-corrected absorbance values for IgG
ELISAs conducted with sera collected pre-treatment (B: 2 weeks post-inoculation), and at 2 and 4 weeks post-treatment (C,D: 6 and 8 weeks post-inoculation).
Serum samples were diluted 1:100 (B) or 1:700 (C,D) and tested against whole cell lysate of B. burgdorferi strain that was used for infection. Shown are individual
values, medians with 95% CI. ∗ indicates p < 0.05 (two-way ANOVA with Holm-Sidak post-tests). Pre-immune sera from individual mice were used as a negative
control at 1:100 dilution (dotted lines in B–D). There was no difference between pre-immune (non-specific) IgG levels of DIO and NW mice (p > 0.05; as determined
by unpaired parametric t-test).
the blood-brain barrier efficiently, tigecycline concentration
in the brain is approximately 10 times lower than in serum
(Nau et al., 2010). It is therefore possible that tigecycline
did not reach sufficiently high concentrations in the brain to
reduce bacterial load in this organ. Furthermore, treatment
with the “NW dose” but not the “Obese dose” of tigecycline
resulted in significantly increased bacterial DNA burden in
kidney compared to mock-treated mice. Higher doses of this
antibiotic may have been required for effective antimicrobial
treatment in kidneys. Nonetheless, this hypothesis does not
explain why bacterial DNA burden was greater in kidneys of
mice treated with a normal-weight dose of tigecycline than
in untreated mice, where kidneys were largely negative for
B. burgdorferi DNA. Tigecycline has not been associated with
significant clinical nephrotoxicity (Estes and Derendorf, 2010).
However, one possibility is that lower dose tigecycline treatment
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affected kidney microstructure or function, rendering this organ
more sensitive to bacterial colonization, or less susceptible to
clearance of bacteria and their debris by phagocytic cells, but
that this colonization/persistence advantage was eradicated at
a higher drug dose. Since we did not examine pathology in
kidney, which does not develop prominent pathology in inbred
laboratory mouse strains infected with B. burgdorferi (Schaible
et al., 1989; Barthold et al., 1990, 1991; Schneider et al., 2013),
we do not know if the presence of bacterial DNA in these
organs was clinically meaningful, or if tigecycline treatment was
associated with histological changes which might affect bacterial
colonization and persistence.
Persistence of B. burgdorferi in tissues has been explored
in numerous studies using various antibiotic combinations,
different animal models and distinct B. burgdorferi strains
(Straubinger et al., 1997; Hodzic et al., 2008, 2014; Barthold
et al., 2010; Yrjänäinen et al., 2010; Bockenstedt et al., 2012;
Embers et al., 2012; Pavia and Wormser, 2014). In the
majority of cases, bacterial DNA can be detected in animal
tissues post-antibiotic treatment; however, controversy exists on
viability and infectious status of persistent bacteria (Wormser
and Schwartz, 2009; Bockenstedt and Radolf, 2014; Pavia and
Wormser, 2014). Bacteria were not recovered by culture in
experiments described here, and we cannot therefore comment
on the effect of antibiotics on persistence and infectivity of
live B. burgdorferi in the context of DIO. Bacterial DNA
was detected in 14% (27/198) and 15% (30/199) of tissues
from tigecycline-treated DIO and NW mice, respectively, which
is comparable to the percentage of qPCR-positive tissues in
immunocompetent mice treated by ceftriaxone or tigecycline
reported in previous studies (Hodzic et al., 2008; Barthold
et al., 2010). Furthermore, Barthold et al. (2010) observed 27%
(11/40) qPCR positive-tissues in mice treated with a four-
times higher (50 mg/kg) dose of tigecycline than was used in
the present study, and it is therefore unlikely that increasing
the tigecycline dose would change outcomes of treatment in
DIO or NW mice. In contrast, lowering the tigecycline dose
might alter treatment outcomes in both DIO and NW mice.
However, potential differences between bacterial burden in
DIO and NW mice would likely stem from ineffective dosing
rather than the effects of DIO; as estimated from the value
of fAUC0−24/MIC, a lower tigecycline dose would likely not
be effective against the B. burgdorferi strain TMB79 used in
this study (Crandon et al., 2009; Koomanachai et al., 2009).
Alternative results might have been also observed if DIO
mice were treated with another antibiotic, since obesity can
affect pharmacokinetic and pharmacodynamic parameters of
individual drugs differently (Falagas and Karageorgopoulos,
2010).
In the present study, DIO mice displayed delayed and
attenuated production of B. burgdorferi-specific IgGs within the
8-week period of this study. Obesity is known to reduce the
efficacy of vaccination against a number of viral pathogens, and to
impair antibody production in response to influenza vaccination,
T cell-independent antigen and S. aureus infection (Sheridan
et al., 2012; Teague et al., 2013; Farnsworth et al., 2015; Painter
et al., 2015). Longer infectivity studies in DIO mice are warranted
to explore the possibility that impaired B. burgdorferi-specific IgG
production in DIO might contribute to increased susceptibility to
B. burgdorferi reinfection (Nadelman et al., 2012; Rogovskyy and
Bankhead, 2013; Elsner et al., 2015).
CONCLUSION
Here we showed that DIO does not impair tigecycline efficacy
in treating B. burgdorferi infection. Furthermore, our data
indicate that DIO suppresses humoral immune responses to this
pathogen, warranting further investigation of the mechanisms
and possible consequences of this immune suppression in animal
models of DIO and human populations.
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